Exploratory Outcomes
SECONDARY
Levels of relevant laboratory test values and hyperinflammatory parameters over time are shown in eTable 7 and eTable 8 respectively in Post hoc sensitivity analysis showed that there were no significant differences between groups for the primary and secondary end points among patients with a SCOPE score of 6 or higher (eTable 10 in Post hoc analyses showed a significantly lower proportion of patients treated with anakinra with abnormal chest imaging findings by day 15 vs the patients treated with SoC alone (28 patients [62.2%] vs 42 patients [82.4%]; RR, 0.47; 95% CI, 0.23-0.94; 